Ownership and leadership

Michael Kocher

Michael joined Xellia as Chief Executive Officer in October 2023. Prior to joining Xellia, he held the position of Head of Global B2B in Sandoz and Novartis Country President Austria. He has more than a decade of experience in commercial leadership roles at Novartis and Sandoz and extensive experience within the global pharmaceutical and anti-infective industry.

Michael holds both a Master’s degree in Chemistry from Johannes Gutenberg University Mainz and a Master’s in Marketing and Economics from the University of Basel, Switzerland.

Art Fiocco

Arthur J. Fiocco Jr. joined the company as Interim Chief Operations Officer in May 2024. He brings with him a wealth of experience, having held top leadership positions in manufacturing and quality operations at Baxter and Hospira (now part of Pfizer). With Art’s extensive background in the industry, he will lead our Global Product Supply and Quality functions to better support the organization’s goal.

Art holds a Bachelor’s degree in Pharmacy at Temple University in Philadelphia, Pennsylvania USA.

Florian Falch

Florian joined Xellia in September 2023 as Vice President Transformation. Before joining Xellia, he spent more than 8 years at Sandoz where he led various Strategy, Transformation and M&A activities with a focus on the Anti-Infectives portfolio as well as the B2B channel of the company. Prior to that, he worked as a management consultant at KPMG.

Florian holds a Master’s degree in Economics from Lund University, Sweden, as well as a diploma in Management & Law from Management Center Innsbruck, Austria.

Gaël Bernard

Gaël, a French national, has an extensive career in the pharmaceutical industry dating back to 1996, demonstrating a strong track record in driving growth and strategic expansion. Since joining Xellia in 2008, Gaël has held various executive and senior positions, including Vice President of Sales and Marketing and Chief Commercial Officer.

Before Xellia, Gaël worked with both branded and generic pharmaceuticals at Alpharma Pharmaceuticals and Actavis Pharmaceuticals, holding several senior roles such as Global Vice President and CEO in China, Denmark and France.

Gaël's educational background includes degrees from ISPG-ESA3 Business School in Paris, studies at the University of International Business and Economics (UIBE) in China, and executive education from London Business School. In 2023, Gaël began an Executive MBA program at AVT Business School in Denmark.

Søren Hostrup

Søren joined Xellia in 2008 and has since held various positions within Xellia’s legal department. He was promoted to Xellia’s Group General Counsel in 2021. Before joining Xellia, he held positions as attorney-at-law with DONG Energy, Novo Nordisk and Bech-Bruun Law Firm.

Søren holds a Master’s degree in Law from Copenhagen University and a Graduate Diploma in Business Administration (Finance) from Copenhagen Business School.

Vicente Oller Más

Vicente joined Xellia Pharmaceuticals in September 2024 as Chief Financial Officer (CFO). Before that, he was the CFO of the Global B2B business at Sandoz and simultaneously served as the Country CFO for Sandoz Austria.

After finishing his business studies, including an MBA at ESADE and the International Management Program at HEC, he started his career as an auditor at Arthur Andersen in Spain and joined Novartis Spain in 2005.

Having held key financial leadership roles in originator and generics companies across commercial, development and manufacturing units, Vicente brings over 20 years of extensive experience in the pharmaceutical industry to Xellia.